Dendrimer-triglycine-EGF nanoparticles for tumor imaging and targeted nucleic acid and drug delivery

被引:50
作者
Yuan, Quan [2 ]
Lee, Eunmee [1 ]
Yeudall, W. Andrew [1 ,3 ]
Yang, Hu [2 ]
机构
[1] Virginia Commonwealth Univ, Sch Dent, Philips Inst Oral & Craniofacial Mol Biol, Richmond, VA 23298 USA
[2] Virginia Commonwealth Univ, Sch Engn, Dept Biomed Engn, Richmond, VA 23284 USA
[3] Virginia Commonwealth Univ, Massey Canc Ctr, Richmond, VA 23284 USA
关键词
Dendrimer; EGF; Gene delivery; Imaging; siRNA; Gene knockdown; HNSCC; Nanoparticles; Quantum dots; RNAi; Vimentin; YFP; GROWTH-FACTOR RECEPTOR; SQUAMOUS-CELL CARCINOMA; CANCER; HEAD; TRANSFECTION; MOTILITY; THERAPY;
D O I
10.1016/j.oraloncology.2010.07.001
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
We designed an epidermal growth factor (EGF)-containing polyamidoamine (PAMAM) Generation 4 dendrimer vector labeled with quantum dots for targeted imaging and nucleic acid delivery. (1)H NMR, SDS-PAGE, and Western blotting were applied to characterize the synthesized G4.0-GGG-EGF nanoparticles. Targeting efficiency, cell viability, proliferation, and intracellular signal transduction were evaluated using HN12, NIH3T3, and NIH3T3/EGFR cells. We found that EGF-conjugated dendrimers did not stimulate growth of EGFR-expressing cells at the selected concentration. Consistent with this, minimal stimulation of post-receptor signaling pathways was observed. These nanoparticles can localize within cells that express the EGFR in a receptor-dependent manner, whereas uptake into cells lacking the receptor was low. A well characterized vimentin shRNA (shVIM) and yellow fluorescent protein (YFP) siRNA were used to test the delivery and transfection efficiency of the constructed targeted vector. Significant knockdown of expression was observed, indicating that this vector is useful for introduction of nucleic acids or drugs into cells by a receptor-targeted mechanism. (C) 2010 Elsevier Ltd. All rights reserved.
引用
收藏
页码:698 / 704
页数:7
相关论文
共 29 条
[11]   Simultaneous two-color spectral fluorescence lymphangiography with near infrared quantum dots to map two lymphatic flows from the breast and the upper extremity [J].
Hama, Yukihiro ;
Koyama, Yoshinori ;
Urano, Yasuteru ;
Choyke, Peter L. ;
Kobayashi, Hisataka .
BREAST CANCER RESEARCH AND TREATMENT, 2007, 103 (01) :23-28
[12]  
Jakus J, 1996, ONCOGENE, V12, P2369
[13]   Epidermal growth factor receptor biology in head and neck cancer [J].
Kalyankrishna, Shailaja ;
Grandis, Jennifer R. .
JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (17) :2666-2672
[14]   Simultaneous multicolor imaging of five different lymphatic basins using quantum dots [J].
Kobayashi, Hisataka ;
Hama, Yukihiro ;
Koyama, Yoshinori ;
Barrett, Tristan ;
Regino, Celeste A. S. ;
Urano, Yasuteru ;
Choyke, Peter L. .
NANO LETTERS, 2007, 7 (06) :1711-1716
[15]   Apoptotic epidermal growth factor (EGF)-Conjugated block copolymer micelles as a nanotechnology platform for targeted combination therapy [J].
Lee, Helen ;
Hu, Meiduo ;
Reilly, Raymond M. ;
Allen, Christine .
MOLECULAR PHARMACEUTICS, 2007, 4 (05) :769-781
[16]   Designing dendrimers for drug delivery [J].
Liu, MJ ;
Fréchet, JMJ .
PHARMACEUTICAL SCIENCE & TECHNOLOGY TODAY, 1999, 2 (10) :393-401
[17]   The epidermal growth factor receptor as a target for cancer therapy [J].
Mendelsohn, J .
ENDOCRINE-RELATED CANCER, 2001, 8 (01) :3-9
[18]   Henry's law constants of propane, propene, butane, and 2-methylpropane in methanol at 374-490 K [J].
Miyano, Y ;
Fujihara, I ;
Sato, K .
FLUID PHASE EQUILIBRIA, 2006, 240 (01) :56-62
[19]   N-hydroxysuccinimide carbonates and carbamates are useful reactive reagents for coupling ligands to lysines on proteins [J].
Morpurgo, M ;
Bayer, EA ;
Wilchek, M .
JOURNAL OF BIOCHEMICAL AND BIOPHYSICAL METHODS, 1999, 38 (01) :17-28
[20]   Keratin down-regulation in vimentin-positive cancer cells is reversible by vimentin RNA interference, which inhibits growth and motility [J].
Paccione, Rachel J. ;
Miyazaki, Hiroshi ;
Patel, Vyomesh ;
Waseern, Ahmad ;
Gutkind, J. Silvio ;
Zehner, Zendra E. ;
Yeudall, W. Andrew .
MOLECULAR CANCER THERAPEUTICS, 2008, 7 (09) :2894-2903